biote Corp.
NASDAQ:BTMDMedical - Care Facilities
+$0.01 today
- Market cap
- $54.25M
- Beta
- 1.66
- P/E (TTM)
- 4.5
- EPS (TTM)
- $0.51
Volume 0.11M
Average 0.25M
BTMD Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
biote Corp.NASDAQ: BTMD
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue declines year over year
Q1 FY2026 revenue of $44.94M fell 8.3% year over year, behind the -5.6% change in trailing-twelve-month revenue. Sequentially, it fell 3.2% from the prior quarter. Over 3 fiscal years it compounded at +5.2% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 3 analysts of $178M (-7.4%) for the fiscal year ending Dec 2026, a slowdown from the -2.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $44.94M-3.2% QoQ
- Last fiscal yearDec 2025
- $192.22M-2.5% YoY
- LTMMar 2026
- $188.16M-5.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -8.3% | -5.6% | +2.7 pp |
| 1 year | -2.5% | -7.4% | -4.9 pp |
| 3-year CAGR | +5.2% | +0.8% | -4.4 pp |
| 5-year CAGR | +2.8% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 192.22M USD
- Year-over-year change
- -2.5%
- 4-year CAGR
- +8.4%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 192.22M | -2.5% |
| FY2024 | 2024-12-31 | 197.19M | +6.4% |
| FY2023 | 2023-12-31 | 185.36M | +12.4% |
| FY2022 | 2022-12-31 | 164.96M | +18.3% |
| FY2021 | 2021-12-31 | 139.4M | — |
Revenue vs competitors
How BTMD compares with its peers on the latest reported figures
- BTMD's LTM Mar 2026 revenue of $188.16M is the highest of the 11 companies compared; the peer median is $3.14M.
- Its year-over-year change of -5.6% is the 5th highest of 7, against a peer median of +22.9%.
- Over three fiscal years its annual growth of +5.2% compares with a peer median of -3.8%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $188.16M | -5.6% | +5.2% | |
| LTM Mar 2026 | $116.26M | +23.2% | -0.3% | |
| LTM Mar 2026 | $56.64M | +221.8% | -18.5% | |
| LTM Mar 2026 | $54.77M | +22.8% | +7.1% | |
| LTM Mar 2026 | $33.86M | -33.2% | -7.3% | |
| LTM Mar 2026 | $5.13M | +23.0% | +132.0% | |
| LTM Mar 2026 | $1.15M | — | — | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | — | — | |
| LTM Mar 2026 | $0 | -100.0% | -81.5% | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $0 | — | — |
| Peer median (excluding BTMD) | $3.14M | +22.9% | -3.8% | |
Competitors are the stored peer set for BTMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 139.4M | 164.96M | 185.36M | 197.19M | 192.22M |
| Cost of Revenue | 48.82M | 54.58M | 57.88M | 58.13M | 58.13M |
| Gross Profit | 90.58M | 110.38M | 127.48M | 139.06M | 134.09M |
| Gross Margin | 65.0% | 66.9% | 68.8% | 70.5% | 69.8% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 53.96M | 171.1M | 98.83M | 107.45M | 94.97M |
| Operating Expenses | 56.02M | 171.1M | 98.83M | 107.45M | 94.97M |
| Depreciation & Amortization | 1.4M | 2.2M | 794K | 3.57M | 3.67M |
| EBITDA | 35.98M | 7.96M | 39.54M | 15.59M | 53.12M |
| EBITDA Margin | 25.8% | 4.8% | 21.3% | 7.9% | 27.6% |
| Operating Income | 34.56M | (60.72M) | 28.66M | 31.61M | 39.12M |
| Operating Margin | 24.8% | -36.8% | 15.5% | 16.0% | 20.4% |
| Interest Income | 0 | 0 | 0 | 0 | 900K |
| Interest Expense | 1.67M | 4.05M | 6.36M | 11M | 11.86M |
| Other Income / Expenses | (1.66M) | 62.43M | (28.78M) | (30.6M) | (1.54M) |
| Income Before Tax | 32.91M | 1.71M | (123K) | 1.02M | 37.58M |
| Pre-Tax Margin | 23.6% | 1.0% | -0.1% | 0.5% | 19.6% |
| Income Tax Expense | 286K | 388K | 2.68M | 970K | 5.99M |
| Net Income | 32.62M | (969K) | 3.32M | 3.16M | 27.05M |
| Net Margin | 23.4% | -0.6% | 1.8% | 1.6% | 14.1% |
| EPS (Basic) | (0.87) | 0.16 | 0.13 | 0.09 | 0.86 |
| EPS (Diluted) | (0.87) | 0.16 | 0.13 | 0.09 | 0.74 |
| Weighted Avg Shares | 7.57M | 8.06M | 25.71M | 34.27M | 31.28M |
| Weighted Avg Shares (Diluted) | 7.57M | 8.06M | 25.71M | 34.27M | 36.67M |
biote Corp.
NASDAQ:BTMD
Intrinsic Alpha fair value
Locked
Current Price
$1.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.